Novartis highlights new findings in advancing care for patients with 170 abstracts in breast, lung and blood cancers at ASCO and EHA
(Thomson Reuters ONE) -
Novartis International AG /
Novartis highlights new findings in advancing care for patients with 170
abstracts in breast, lung and blood cancers at ASCO and EHA
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
* Latest Phase III research on Afinitor(®) in HER2 positive advanced breast
cancer
* Jakavi(TM) overall survival advantage evaluated in three-year study in
patients with myelofibrosis, a rare and life-threatening blood cancer
* Multi-year studies evaluating deep molecular response with Tasigna(®) in
patients with Ph+CML
* Data from LDK378 trial in ALK+ metastatic non-small cell lung cancer;
supports recent FDA Breakthrough Therapy designation
Basel, May 29, 2013 - Novartis will present new findings in the treatment of
advanced cancers and other diseases with 170 abstracts at two prominent medical
meetings. Research across the extensive Novartis product portfolio and pipeline
showcases the progress in advancing care for patients with cancer and
hematological diseases.
Clinical data from multiple compounds will be featured at the 49th Annual
Meeting of the American Society of Clinical Oncology (ASCO) including
Afinitor(®) (everolimus), Tasigna(®) (nilotinib) and the pipeline compound
LDK378[1]. The 18th Congress of the European Hematology Association (EHA) will
showcase data from Jakavi(TM )(ruxolitinib), Tasigna and Exjade(®)
(deferasirox)[2].
"With a pipeline of more than 25 new molecular entities, we are at the forefront
of a new era in oncology drug development, working towards advances for cancer
patients," said Hervé Hoppenot, President, Novartis Oncology. "These data
demonstrate our progress in furthering research and development through a
highly-targeted approach, matching specific compounds to pathways that are
involved in many difficult-to-treat cancers."
Data highlights include:
Studies examining Afinitorin advanced breast cancer at ASCO
* BOLERO-3 study evaluating potential safety and efficacy of Afinitor in
combination with trastuzumab and vinorelbine in women with HER2 positive
advanced breast cancer who are resistant to trastuzumab and have been pre-
treated with a taxane (abstract #505; June 2, 9:15 AM)
* Updates on Afinitor in hormone receptor-positive (HR+) advanced breast
cancer, including BOLERO-2 sub-analyses (abstract #553, abstract #557,
abstract #558, abstract #561; June 1, 1:15 PM) and a late-breaker examining
genetic variations and their potential correlation with benefit (abstract
#LBA509; June 3, 1:15 PM)
Survival data from Jakaviin myelofibrosis and analysis on bone marrow fibrosis
* At EHA: Three-year data evaluating overall survival advantage, as well as
impact on spleen volume and safety from the Jakavi Phase III COMFORT-II
clinical trial program (abstract #S1111; June 16, 8:00 AM)
* At ASCO and EHA: First evidence of the effect of Jakavi on bone marrow
fibrosis in myelofibrosis patients at 24 and 48 months from a Phase I/II
trial (ASCO abstract #7030; June 4, 8:30 AM; EHA abstract #S591; June
15, 4:15 PM)
Multi-year studies of Tasigna in patients with Ph+ CML
* At ASCO and EHA: Two-year follow-up results from the ENESTcmr study
evaluating sustained deep molecular response following a switch to Tasigna
in patients with Philadelphia chromosome-positive chronic myeloid leukemia
(Ph+ CML) in chronic phase who still had evidence of residual disease after
two or more years of Glivec(®) (imatinib)* therapy (ASCO abstract #7053;
June 2, 8:00 AM; EHA abstract #P133; June 14, 5:45 PM)
* At ASCO and EHA: Four-year update from the ENESTnd study evaluating
molecular response rates of Tasigna compared to Glivec in patients with
newly diagnosed Ph+ CML in chronic phase (ASCO abstract #7052; June 2, 8:00
AM; EHA abstract #P712; June 15, 5:45 PM)
* At ASCO: ENESTnd landmark data correlating early molecular responses in
patients with newly diagnosed Ph+ CML in chronic phase with long-term
outcomes (abstract #7054; June 2, 8:00 AM)
* At EHA: Phase II GIMEMA study evaluating the sustainability of deep
molecular response at five years in patients treated frontline with Tasigna
(abstract #P141; June 14, 5:45 PM)
Survival data from PROMID study of Sandostatin(® )LAR(®) in NET at ASCO
* Follow-up analysis from the PROMID trial evaluating overall survival in
patients with metastatic midgut neuroendocrine tumors (NET) taking
Sandostatin LAR Depot (octreotide acetate for injectable suspension) vs.
placebo (ASCO abstract #4030; June 3, 1:15 PM)
First-in-human study of LDK378 in ALK+ metastatic NSCLC at ASCO
* Updated data from the first-in-human Phase I trial of LDK378, a selective
inhibitor of the cancer target anaplastic lymphoma kinase (ALK), in patients
with ALK+ metastatic non-small cell lung cancer (abstract #8010; June
3, 10:15 AM). In March, the US Food and Drug Administration (FDA) granted
LDK378 Breakthrough Therapy designation, a status intended to expedite the
development and review of drugs that treat serious or life-threatening
conditions
Multi-year analysis of iron overload association with morbidity risk in
untreated thalassemia intermedia patients at EHA
* Analysis of association between iron overload and morbidity risk in patients
with thalassemia intermedia, a form of non-transfusion-dependent thalassemia
(NTDT), over an 11-year period. This retrospective study examined 52
patients with no history of transfusion or iron chelation, from
comprehensive care centers in Italy, Lebanon, Oman, Iran and Egypt (abstract
#S1172; June 16, 10:30 AM)
Additional pipeline research in melanoma, breast cancer and solid tumors at ASCO
* Initial results from a Phase I study of LGX818 in patients with BRAF V600
mutant advanced or metastatic melanoma (abstract #9028; June 3, 8:00 AM)
* Preliminary results from a Phase Ib/II open-label, dose-escalation study of
LGX818 + MEK162** in BRAF V600-dependent advanced solid tumors (abstract
#9029; June 3, 8:00 AM)
* Results from the first in-human study of the PI3K inhibitor BYL719 in
patients with PIK3CA mutant ER-positive metastatic breast cancer (abstract
#2531; June 4, 8:00 AM)
About Afinitor (everolimus)
Everolimus is approved as Afinitor(®) in the European Union (EU) for the
treatment of hormone receptor-positive, HER2 negative (HR+/HER2 negative)
advanced breast cancer, in combination with exemestane, in postmenopausal women
without symptomatic visceral disease after recurrence or progression following a
non-steroidal aromatase inhibitor. In the United States (US), Afinitor is
approved for the treatment of postmenopausal women with advanced hormone
receptor-positive, HER2 negative breast cancer (advanced HR+/HER2 negative) in
combination with exemestane after failure of treatment with letrozole or
anastrozole.
Afinitor(®) (everolimus) tablets is approved in more than 95 countries including
the US and throughout the EU in the oncology settings of advanced renal cell
carcinoma (RCC) following progression on or after vascular endothelial growth
factor (VEGF)-targeted therapy, and in the US and EU for locally advanced,
metastatic or unresectable progressive neuroendocrine tumors of pancreatic
origin (pNET).
Everolimus is also approved as Votubia(®) (everolimus) tablets in the EU for the
treatment of adult patients with renal angiomyolipoma associated with tuberous
sclerosis complex (TSC) who are at risk of complications (based on factors such
as tumor size or presence of aneurysm, or presence of multiple or bilateral
tumors) but who do not require immediate surgery. The evidence is based on
analysis of change in sum of angiomyolipoma volume. Votubia is also approved in
the EU for the treatment of patients aged 3 years and older with subependymal
giant cell astrocytoma (SEGA) associated with TSC, who require therapeutic
intervention but are not amenable to surgery. The evidence is based on analysis
of change in SEGA volume. Further clinical benefit, such as improvement in
disease-related symptoms, has not been demonstrated.
Everolimus is also available from Novartis for use in certain non-oncology
patient populations under the brand names Certican(®) and Zortress(®) and is
exclusively licensed to Abbott and sublicensed to Boston Scientific for use in
drug-eluting stents.
Indications vary by country and not all indications are available in every
country. The safety and efficacy profile of everolimus has not yet been
established outside the approved indications. Because of the uncertainty of
clinical trials, there is no guarantee that everolimus will become commercially
available for additional indications anywhere else in the world.
Afinitor Important Safety Information
Afinitor/Votubia can cause serious side effects including lung or breathing
problems, infections (including sepsis), and kidney failure, which can lead to
death. Mouth ulcers and mouth sores are common side effects. Afinitor/Votubia
can affect blood cell counts, kidney and liver function, and blood sugar,
cholesterol, and triglyceride levels. Afinitor/Votubia may cause fetal harm in
pregnant women. Highly effective contraception is recommended for women of
child-bearing potential while receiving Afinitor/Votubia and for up to eight
weeks after ending treatment. Women taking Afinitor/Votubia should not breast
feed. Fertility in women and men may be affected by treatment with
Afinitor/Votubia.
The most common adverse drug reactions (incidence >=10 percent) are mouth
ulcers, skin rash, feeling tired or weak, diarrhea, nausea, decreased appetite,
infections (including upper respiratory tract infection, low level of red blood
cells, abnormal taste, inflammation of lung tissue, weight loss, swelling of
extremities or other parts of the body, nose bleeds, itching, vomiting, high
level of blood cholesterol, headache, high level of blood sugar, cough,
spontaneous bleeding or bruising, and breathlessness. The most common Grade 3-4
adverse drug reactions (incidence >=2 percent) are mouth ulcers, feeling tired
or weak, infections, inflammation of lung tissue, diarrhea, spontaneous bleeding
or bruising, low white blood cells (a type of blood cell that fights infection),
and breathlessness. Cases of hepatitis B reactivation, blood clots in the lung
or legs, and menstruation disorders such as absence of periods have been
reported. Abnormalities were observed in hematology and clinical chemistry
laboratory tests.
Please see full Prescribing Information available at www.afinitor.com.
About Jakavi (ruxolitinib)
Jakavi(®) (ruxolitinib) is an oral inhibitor of the JAK 1 and JAK 2 tyrosine
kinases and was approved by the European Commission in August 2012 for the
treatment of disease-related splenomegaly or symptoms in adult patients with
primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post-
polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis.
Jakavi is approved in more than 35 countries, including the member states of the
European Union, Canada and some countries in Asia, Latin and South America.
Additional worldwide regulatory filings are underway.
Novartis licensed ruxolitinib from Incyte Corporation for development and
commercialization outside the United States. Both the European Commission and
the US Food and Drug Administration (FDA) granted ruxolitinib orphan drug status
for myelofibrosis. Jakavi is marketed in the United States by Incyte Corporation
under the name Jakafi(®) for the treatment of patients with intermediate or
high-risk myelofibrosis.
The recommended starting dose for Jakavi is 15 mg twice daily for patients with
a platelet count between 100,000cubic millimeters (mm(3)) and 200,000 mm(3),and
20 mg twice daily for patients with a platelet count of >200,000 mm(3). Doses
may be titrated based on safety and efficacy. There is limited information to
recommend a starting dose for patients with platelet counts between
50,000/mm(3) and <100,000/mm(3). The maximum recommended starting dose in these
patients is 5 mg twice daily and patients should be titrated cautiously.
Jakavi is a registered trademark of Novartis AG in countries outside the United
States. Jakafi is a registered trademark of Incyte Corporation.
Jakavi Important Safety Information
Jakavi(®) can cause serious side effects, including a decrease in blood cell
count and infections. Complete blood count monitoring is recommended. Dose
reduction or interruption may be required in patients with severe hepatic or
renal impairment or in patients developing hematologic adverse reactions such as
thrombocytopenia, anemia and neutropenia. Dose reductions are also recommended
when Jakavi is co-administered with strong CYP3A4 inhibitors or fluconazole. Use
of Jakavi during pregnancy is not recommended and women should avoid becoming
pregnant during Jakavi therapy. Women taking Jakavi should not breast feed.
The most common adverse drug reactions, occurring at any level of severity
(incidence >10%) are urinary tract infections, anemia, thrombocytopenia,
neutropenia, hypercholesterolemia, dizziness, headache, alanine
aminotransaminase increased, asparte aminotransferase increased, bruising,
bleeding and increased blood pressure. Other common adverse drug reactions
(incidence 1 to 10%) are herpes zoster, weight gain, flatulence and tuberculosis
(1%). Progressive multifocal leukencephalopathy (PML) has been reported.
Physicians should be alert for neuropsychiatric symptoms suggestive of PML.
Please see full Prescribing Information available at www.jakavi.com.
About Tasigna (nilotinib)
Tasigna(®) (nilotinib) is approved in more than 90 countries for the treatment
of chronic phase and accelerated phase Philadelphia chromosome-positive chronic
myelogenous leukemia (Ph+ CML) in adult patients resistant or intolerant to at
least one prior therapy, including Glivec, and for the treatment of adult
patients with newly diagnosed Ph+ CML in chronic phase. Take twice daily 12
hours apart. Do not take with food. No food to be consumed for 2 hours before or
one hour after dosing. Avoid grapefruit juice and CYP3A4 inhibitors.
Tasigna Important Safety Information
Use with caution in patients with uncontrolled or significant cardiac disease
and in patients who have or may develop prolongation of QTc. Low levels of
potassium or magnesium must be corrected prior to Tasigna administration.
Monitor closely for an effect on the QTc interval. Baseline ECG is recommended
prior to initiating therapy and as clinically indicated. Uncommon cases (0.1 to
1%) of sudden death have been reported in clinical studies in patients with
significant risk factors.
Use with caution in patients with liver impairment, with a history of
pancreatitis and with total gastrectomy. Patients with rare hereditary problems
of galactose intolerance, severe lactase deficiency or glucose-galactose
malabsorption should not use Tasigna. Tasigna may cause fetal harm in pregnant
women. Women taking Tasigna should not breastfeed.
The most frequent Grade 3 or 4 adverse events are hematological (neutropenia and
thrombocytopenia) which are generally reversible and usually managed by
withholding Tasigna temporarily or dose reduction. Monitor blood counts
regularly. Pancreatitis has been reported. The most frequent non-hematologic
adverse events were rash, pruritus, nausea, fatigue, headache, alopecia,
myalgia, constipation and diarrhea. Most of these adverse events were mild to
moderate in severity.
Please see full Prescribing Information available at www.tasigna.com.
About Glivec (imatinib)
Glivec(®) (imatinib) is approved in more than 110 countries for the treatment of
all phases of Ph+ CML, for the treatment of adult patients with KIT (CD117)-
positive gastrointestinal stromal tumors (GIST), which cannot be surgically
removed and/or have metastasized and for the treatment of adult patients
following complete surgical removal of KIT+ GIST. Take with food and a large
glass of water.
Glivec Important Safety Information
Glivec can cause fetal harm in pregnant woman. Glivec has been associated with
severe edema (swelling) and serious fluid retention. Cytopenias (anemia,
neutropenia, thrombocytopenia) are common, generally reversible and usually
managed by withholding Glivec or dose reduction. Monitor blood counts regularly.
Severe congestive heart failure and left ventricle dysfunction, severe liver
problems including cases of fatal liver failure and severe liver injury
requiring liver transplants have been reported. Use caution in patients with
cardiac dysfunction and hepatic dysfunction. Monitor carefully.
Bleeding may occur. Severe gastrointestinal (GI) bleeding has been reported in
patients with KIT+ GIST. Skin reactions, hypothyroidism in patients taking
levothyroxine replacement, GI perforation, in some cases fatal and tumor lysis
syndrome, which can be life threatening, have also been reported with Glivec.
Correct dehydration and high uric acid levels prior to treatment. Long-term use
may result in potential liver, kidney, and/or heart toxicities; immune system
suppression may also result from long-term use. In patients with
hypereosinophilic syndrome and heart involvement, cases of heart disease have
been associated with the initiation of Glivec therapy. Growth retardation has
been reported in children taking Glivec. The long-term effects of extended
treatment with Glivec on growth in children are unknown.
The most common side effects include fluid retention, muscle cramps or pain and
bone pain, abdominal pain, loss of appetite, vomiting, diarrhea, decreased
hemoglobin, abnormal bleeding, nausea, fatigue and rash.
Please see full Prescribing Information available at www.glivec.com.
About Sandostatin LAR (octreotide acetate for injectable suspension)
Sandostatin(®) LAR(®) is a long-acting, injectable depot formulation of
octreoide acetate that is indicated for the treatment of patients with
acromegaly who are adequately controlled on s.c. treatment with Sandostatin; in
patients in whom surgery or radiotherapy is inappropriate or ineffective; in the
interim period until radiotherapy becomes fully effective. Relief of symptoms
associated with functional gastro-entero-pancreatic endocrine tumors: carcinoid
tumors with features of the carcinoid syndrome, VIPomas, glucagonomas,
gastrinomas/Zollinger-Ellison syndrome, insulinomas, GRFomas. Treatment of
patients with advanced neuroendocrine tumors of the midgut or unknown primary
tumor location.
Sandostatin LAR was first approved in France in June 1995 and is currently
approved in 95 countries. For more than a decade, Sandostatin LAR has achieved a
long-standing track record of sustained efficacy with a well-established safety
profile.
Not all indications are approved in every country.
Sandostatin LAR Important Safety Information
Indication
Sandostatin LAR is indicated for:
* Treatment of patients with Acromegaly:
* who are adequately controlled on s.c. treatment with Sandostatin;
* in whom surgery or radiotherapy is inappropriate or ineffective; in the
interim period until radiotherapy becomes fully effective.
* Treatment of patients with symptoms associated with functional gastro-
entero-pancreatic endocrine tumors in whom symptoms are adequately
controlled on s.c. treatment with Sandostatin: carcinoid tumors with
features of the carcinoid syndrome, VIPomas, glucagonomas,
gastrinomas/Zollinger-Ellison syndrome, insulinomas, GRFomas.
* Treatment of patients with advanced neuroendocrine tumors of the midgut or
unknown primary tumor location.
Contraindications
Known hypersensitivity to octreotide or to any of the excipients
Warnings and Precautions
Uncommon cases of bradycardia have been reported. Dose adjustments of drugs such
as beta-blockers, calcium channel blockers, or agents to control fluid and
electrolyte balance, may be necessary.
Gallbladder abnormalities may occur. Patients should be monitored periodically.
Hypoglycemia or hyperglycemia may occur. Blood glucose levels should be
monitored when treatment is initiated or when the dose is altered. Antidiabetic
treatment should be adjusted accordingly. Caution in patients with insulinomas
or diabetes mellitus. These patients should be monitored closely.
Octreotide may alter absorption of dietary fats in some patients. Monitoring of
vitamin B12 levels is recommended in patients with a history of vitamin B12
deprivation.
Hypothyroidism may occur. Thyroid function should be monitored in patients
receiving prolonged treatment with octreotide.
Caution in females of child-bearing potential. Patients should be advised to use
adequate contraception. Use in pregnant women only under compelling
circumstances. Do not breast-feed during treatment.
Drug Interactions
Monitoring and possible dose adjustment may be required when used with
cyclosporine, cimetidine or bromocriptine. Drugs mainly metabolized by CYP3A4
and which have a low therapeutic index should be used with caution.
Adverse Events
The most commonly reported adverse reactions in clinical trials were diarrhea,
abdominal pain, nausea, flatulence headache, cholelithiasis, hyperglycemia and
constipation. Other commonly reported adverse reactions were dizziness,
localized pain, biliary sludge, thyroid dysfunction (e.g., decreased thyroid
stimulating hormone [TSH], decreased Total T4, and decreased Free T4), loose
stools, impaired glucose tolerance, vomiting, asthenia, and hypoglycemia. In
rare instances, gastrointestinal side effects may resemble acute intestinal
obstruction, with progressive abdominal distension, severe epigastric pain,
abdominal tenderness and guarding. In very rare instances, acute pancreatitis
has been reported within the first hours or days of treatment and resolved on
withdrawal of the drug. Cholelithiasis-induced pancreatitis has been reported on
long-term treatment.
Post-marketing adverse reactions include: anaphylaxis, allergy/hypersensitivity
reactions, urticaria, acute pancreatitis, acute hepatitis without cholestasis,
cholestatic hepatitis, cholestasis, jaundice, cholestatic jaundice, arrhythmia,
increased alkaline phosphatase levels, and increased gamma glutamyl transferase
levels.
Please see full Prescribing Information for Sandostatin LAR Depot.
About Exjade (deferasirox)
Exjade is an oral iron chelation therapy indicated for the treatment of chronic
iron overload due to frequent blood transfusions (>=7 ml/kg/month of packed red
blood cells) in patients with beta-thalassemia aged 6 years and older). It is
also indicated for the treatment of chronic iron overload due to blood
transfusions when deferoxamine therapy is contraindicated or inadequate in the
following patient groups: patients with beta-thalassemia major with iron
overload due to frequent blood transfusions (>=7 ml/kg/month of packed red blood
cells) aged 2 to 5 years; patients with beta-thalassemia major with iron
overload due to infrequent blood transfusions (<7 ml/kg/month of packed red
blood cells) aged 2 years and older; and patients with other anemias aged 2
years and older. Exjade is also indicated for the treatment of chronic iron
overload requiring chelation therapy when deferoxamine therapy is
contraindicated or inadequate in patients with non-transfusion-dependent
thalassemia syndromes aged 10 years and older.
It is approved in more than 100 countries including the US, Switzerland, Japan
and countries comprising the EU. The approved indication may vary depending upon
the individual country.
Exjade Important Safety Information
Exjade is contraindicated in patients with an estimated creatinine clearance <60
mL/min, with hypersensitivity to the active substance or any of the excipients,
or in combination with other iron chelator therapies. Exjade is not recommended
in patients with severe hepatic impairment.
There have been postmarketing reports of acute renal failure, hepatic failure
and cytopenias. Renal failure requiring temporary or permanent dialysis, renal
tubulopathy and interstitial nephritis have been reported. Upper
gastrointestinal ulceration and hemorrhage, sometimes fatal, have been reported.
Caution should be used in elderly patients due to a higher frequency of adverse
reactions. Exjade is not recommended in patients with a short life expectancy
(e.g., high-risk myelodysplastic syndromes), especially when co-morbidities
could increase the risk of adverse events.
Skin rashes, serious hypersensitivity reactions, decreased hearing and lens
opacities have been reported. The most common adverse reactions are nausea,
vomiting, diarrhea, abdominal pain, rash, pruritus, non-progressive increases in
serum creatinine, increased transaminases, abdominal distension, constipation,
dyspepsia, proteinuria and headache.
Please see full Prescribing Information available at www.exjade.com .
About LDK378, LGX818, BYL719 and MEK162
Because these are investigational compounds, the safety and efficacy profile of
LDK378, LGX818, BYL719 and MEK162 have not yet been established. Access to these
investigational compounds is available only through carefully controlled and
monitored clinical trials. These trials are designed to understand better the
potential benefits and risks of the compound. Because of uncertainty of clinical
trials, there is no guarantee that LDK378, LGX818, BYL719 and MEK162 will ever
be commercially available anywhere in the world.
Disclaimer
The foregoing release contains forward-looking statements that can be identified
by terminology such as "Breakthrough Therapy," "will," "potential," "advancing,"
"pipeline," "progress," "investigational," "working towards" or similar
expressions, or by express or implied discussions regarding potential new
indications or labeling for existing products, potential submissions for or
approvals in any indication for investigational compounds, or regarding
potential future revenues from such compounds and products. You should not place
undue reliance on these statements. Such forward-looking statements reflect the
current views of management regarding future events, and involve known and
unknown risks, uncertainties and other factors that may cause actual results to
be materially different from any future results, performance or achievements
expressed or implied by such statements. There can be no guarantee that of the
investigational compounds referred to in this release will be submitted or
approved for sale in any market, or that the existing products referred to in
this release will be submitted or approved for any additional indications or
labeling in any market. Nor can there be any guarantee that any of the
investigational compounds or products referred to in this release will achieve
any particular levels of revenue in the future. In particular, management's
expectations regarding such products could be affected by, among other things,
unexpected clinical trial results, including unexpected new clinical data and
unexpected additional analysis of existing clinical data; unexpected regulatory
actions or delays or government regulation generally; competition in general;
government, industry and general public pricing pressures; unexpected
manufacturing issues; the company's ability to obtain or maintain patent or
other proprietary intellectual property protection; the impact that the
foregoing factors could have on the values attributed to the Novartis Group's
assets and liabilities as recorded in the Group's consolidated balance sheet,
and other risks and factors referred to in Novartis AG's current Form 20-F on
file with the US Securities and Exchange Commission. Should one or more of these
risks or uncertainties materialize, or should underlying assumptions prove
incorrect, actual results may vary materially from those anticipated, believed,
estimated or expected. Novartis is providing the information in this press
release as of this date and does not undertake any obligation to update any
forward-looking statements contained in this press release as a result of new
information, future events or otherwise.
About Novartis
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative medicines,
eye care, cost-saving generic pharmaceuticals, preventive vaccines and
diagnostic tools, over-the-counter and animal health products. Novartis is the
only global company with leading positions in these areas. In 2012, the Group
achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted
to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and
amortization charges). Novartis Group companies employ approximately 129,000
full-time-equivalent associates and operate in more than 140 countries around
the world. For more information, please visit http://www.novartis.com.
Novartis is on Twitter. Sign up to follow (at)Novartis at
http://twitter.com/novartis.
*Known as Gleevec(®) (imatinib mesylate) tablets in the US, Canada and Israel.
** MEK162 is licensed from Array BioPharma Inc.
References
1 American Society of Clinical Oncology. ASCO Annual '13 Meeting Program.
Available at: http://abstracts2.asco.org/. Accessed May 2013.
2 European Hematology Association. EHA Annual Meeting Program. Available at:
https://b-com.mci-group.com/EventProgramme/EHA18.aspx. Accessed May 2013.
# # #
Novartis Media Relations
Central media line: +41 61 324 2200
Eric Althoff Maureen Byrne
Novartis Global Media Relations Novartis Oncology
+41 61 324 7999 (direct) +1 862 778 1518 (direct)
+41 79 593 4202 (mobile) +1 973 714 0063 (mobile)
eric.althoff(at)novartis.com maureen.byrne(at)novartis.com
e-mail: media.relations(at)novartis.com
For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis
For questions about the site or required registration, please contact:
journalisthelp(at)thenewsmarket.com.
Novartis Investor Relations
Central phone: +41 61 324 7944 North America:
Samir Shah +41 61 324 7944 Stephen Rubino +1 862 778 8301
Pierre-Michel Bringer +41 61 324 1065 Jill Pozarek +1 212 830 2445
Thomas Hungerbuehler +41 61 324 8425 Edwin Valeriano +1 212 830 2456
Isabella Zinck +41 61 324 7188
e-mail: investor.relations(at)novartis.com e-mail:
investor.relations(at)novartis.com
Media release (PDF):
http://hugin.info/134323/R/1705343/564111.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Novartis International AG via Thomson Reuters ONE
[HUG#1705343]
Unternehmensinformation / Kurzprofil:
Datum: 29.05.2013 - 07:16 Uhr
Sprache: Deutsch
News-ID 264128
Anzahl Zeichen: 35512
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 226 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Novartis highlights new findings in advancing care for patients with 170 abstracts in breast, lung and blood cancers at ASCO and EHA"
steht unter der journalistisch-redaktionellen Verantwortung von
Novartis International AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
